1-3 of 3
Timothy J. McDonnell
Close
Save search
Sort by
Journal Articles

Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL

Free
Arushi Khurana, Raphael Mwangi, Loretta J. Nastoupil, Patrick M. Reagan, Umar Farooq, Jason T. Romancik, Timothy J. McDonnell, Shaun M. Riska, lzidore S. Lossos, Brad S. Kahl, Peter Martin, Thomas E. Witzig, James R. Cerhan, Christopher R. Flowers, Grzegorz S. Nowakowski, Matthew J. Maurer
Journal: Blood Advances
Blood Adv (2024) 8 (16): 4414–4422.
https://doi.org/10.1182/bloodadvances.2024012838
Published: 2024
Includes: Supplemental data
Journal Articles

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Free
Clinical Trials & Observations
Hua-Jay J. Cherng, Stefan K. Alig, Yasuhiro Oki, Loretta J. Nastoupil, Luis Fayad, Sattva S. Neelapu, Francesco Turturro, Fredrick Hagemeister, Alexander F. M. Craig, Charles W. Macaulay, Maria Alma Rodriguez, Hun Ju Lee, Timothy J. McDonnell, Christopher R. Flowers, Francisco Vega, Michael R. Green, Lei Feng, David M. Kurtz, Ash A. Alizadeh, R. Eric Davis, Jason R. Westin
Journal: Blood Advances
Blood Adv (2023) 7 (7): 1137–1145.
https://doi.org/10.1182/bloodadvances.2022008174
Published: 2023
Journal Articles

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy

Free
Clinical Trials & Observations
Zimu Gong, L. Jeffrey Medeiros, Jorge E. Cortes, Zi Chen, Lan Zheng, Yan Li, Shi Bai, Pei Lin, Roberto N. Miranda, Jeffrey L. Jorgensen, Timothy J. McDonnell, Wei Wang, Hagop M. Kantarjian, Shimin Hu
Journal: Blood Advances
Blood Adv (2017) 1 (26): 2541–2552.
https://doi.org/10.1182/bloodadvances.2017011858
Published: 2017
Includes: Supplemental data